(IN BRIEF) AstraZeneca’s Alexion has secured European Commission approval for Koselugo (selumetinib), the first targeted therapy available to adults with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The approval is based on the KOMET Phase III trial, … Read the full press release
Posted in Business, Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged adult NF1 treatment, Alexion, American Society of Clinical Oncology, APHP, ASCO 2025, AstraZeneca, AstraZeneca Expands Rare Disease Portfolio with EU Approval of Koselugo for Adults with NF1 Tumours, European Commission approval, European Union, Henri Mondor Hospital, Japan approval, KOMET Phase III trial, Koselugo, Marc Dunoyer, MEK inhibitor, neurofibromatosis type 1, NF1, Paris East University, Pierre Wolkenstein, plexiform neurofibromas, PN, rare disease therapy, selumetinib, The Lancet, tumour response rate, UPEC
(IN BRIEF) A recent comprehensive review published in The Lancet Regional Health Europe offers insights into the risk factors and management strategies for atrial fibrillation (AF), a prevalent heart rhythm disorder affecting millions globally. Conducted by researchers from the University … Read the full press release
Posted in Business, Education, Environment, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged atrial fibrillation, Dr Eduard Shantsila, Management, Professor Deirdre Lane, Professor Gregory Lip, risk factors, Seoul National University College of Medicine, The Lancet, University of Liverpool
5-year results of international TARGIT-A clinical trial support targeted intraoperative radiotherapy (TARGIT) delivered with the ZEISS INTRABEAM as non-inferior to external beam radiotherapy (EBRT) for selected early stage breast cancer patients. Jena, Germany, 27-11-2013 — /EuropaWire/ — Results of the TARGIT-A clinical … Read the full press release
Posted in Electronics & Machinery, Germany, Healthcare, Science, Technology
Tagged breast cancer, early stage breast cancer, external beam radiotherapy, new breast cancer clinical trial, post-surgical radiotherapy treatment, Professor Jayant S. Vaidya FRCS MD PhD, Professor Michael Baum, targeted intraoperative radiotherapy, targeted radiotherapy during surgery, TARGIT-A clinical trial, The Lancet, ZEISS, ZEISS INTRABEAM
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?